Plumbline Life Sciences, Inc. engages in the manufacturing of drugs for animals. It develops deoxyribonucleic acid (DNA)-based vaccines and therapies for animals using plasmid-based DNA delivery and expression technology by electroporation to optimize an animal's natural biological and immunological potential. The company's solutions include growth hormone releasing hormone (GHRH), a naturally occurring molecule; and an electroporation technology for delivering plasmids into skeletal muscle cells and skin. Its products are used for dog cancer/anemia, equine laminitis, cat renal failure/anemia, dog renal failure/anemia, and swine GHRH. The company was founded on January 2, 2014 and is headquartered at Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company